CREATIVE BIOTHERAPEUTICS, LLC
Monoclonal antibody therapeutics targeting extracellular GRP78 (ecGRP78) to treat drug-resistant brain cancers and metastases
- Sector
- Biotech
- Headquarters
- GURNEE, IL
- Latest Form D
- $150K, Aug 2023
- Total capital
- $2.4M
- Federal grants
- $2.1M
- 3 awards · 2021–2024
- Rank in peer group#338 of 502
- Private capital raised
- $330K
- 3 Form D · last Aug 2023
- 38 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 10 pending · first 2021
- Rank in peer group#41 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Developing a Novel Biologic Therapy to Eradicate Brain Cancer and Brain Metastasis$400K
- Private capital raisedForm D · SEC · 3rd filing$150K
- Private capital raisedForm D · SEC · 2nd filing$80K
- Federal grantNSF · Phase II · SBIR Phase II: Stress Pathway Inhibition To Prevent COVID-19 Infection (COVID-19)$1.4M
- Private capital raisedForm D · SEC · 1st filing$100K
- Federal grantNSF · Phase I · SBIR Phase I: Stress Pathway Inhibition Prevents COVID-19 Infection (COVID-19)$256K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
11months
from CREATIVE BIOTHERAPEUTICS, LLC’s first federal award to its first private round.
- First federal award · Jan 2021
- NSF · $256K
- First Form D · Dec 2021
- $100K · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#41 · top 8%
- Linked publications#8 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Donald Kay DavidsonResearcherExecutive OfficerLinked by $400K in grants as PI
- Anita Kay DavidsonExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 12- GrantedAntivirus Proteins Having A Kringle 5 SubunitUSPTOUS 12,060,410
- GrantedGRP78 Antagonist That Block Binding Of Receptor Tyrosine Kinase Orphan Receptors As Immunotherapy Anticancer AgentsUSPTOUS 10,905,750
- PendingExtracellular GRP78 Inhibitors For The Removal Of Treatment Resistant CancersUSPTOApplication 63697155
Show all 12 patent records
- Antivirus Proteins Having A Kringle 5 SubunitAug 13, 2024 · US 12,060,410Granted
- GRP78 Antagonist That Block Binding Of Receptor Tyrosine Kinase Orphan Receptors As Immunotherapy Anticancer AgentsFeb 2, 2021 · US 10,905,750Granted
- Extracellular GRP78 Inhibitors For The Removal Of Treatment Resistant CancersApplication 63697155Pending
- Extracellular GRP78 Inhibitors For The Removal Of Treatment Resistant CancersApplication 63666560Pending
- GRP78 Antagonists For Alzheimer's TreatmentApplication 63653374Pending
- GRP78 Antagonists For Cancer TreatmentApplication 63564379Pending
- GRP78 Antagonists For Cancer TreatmentApplication 63599963Pending
- GRP78 Antagonists For Cancer TreatmentApplication 63599966Pending
- Antivirus Proteins Having A Kringle 5 SubunitApplication PCTUS2021055329Pending
- GRP78 Antagonists For Alzheimer's TreatmentApplication PCTUS2025031760Pending
- Extracellular GRP78 Inhibitors For The Removal Of Treatment Resistant CancersApplication 19587543Pending
- Extracellular GRP78 Inhibitors For The Removal Of Treatment Resistant CancersApplication PCTUS2024056398Pending
Recent research by its founders
- Inhibition of cell surface GRP78 on brain tumors reverses drug resistance and stops cancer stem cell expansion20260 cites
- Abstract A060: GRP78 and cytokine inhibition displays complete regression of ovarian tumors in mice20250 cites
- Monocyte-driven inflamm-aging reduces intestinal barrier function in females202420 cites
Related companies, and why
- Chinook TherapeuticsSimilar federal contract value in Biotech · null in contracts
- DUPAGE MEDICAL TECHNOLOGY, INC.Similar federal contract value in Biotech · null in contracts
- SEEDLING BIOSYSTEMS INC.Similar federal contract value in Biotech · null in contracts
- ReEngage Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Pana Bio, Inc.Similar federal contract value in Biotech · null in contracts
- WiTii Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .